268 related articles for article (PubMed ID: 2461797)
1. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b.
Mistry JS; Jani JP; Morris G; Mujumdar RB; Reynolds IJ; Sebti SM; Lazo JS
Cancer Res; 1992 Feb; 52(3):709-18. PubMed ID: 1370650
[TBL] [Abstract][Full Text] [Related]
3. Liblomycin-mediated DNA cleavage in human head and neck squamous carcinoma cells and purified DNA.
Wassermann K; Zwelling LA; Lown JW; Hartley JA; Nishikawa K; Lin JR; Newman RA
Cancer Res; 1990 Mar; 50(6):1732-7. PubMed ID: 1689610
[TBL] [Abstract][Full Text] [Related]
4. In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma.
Zuckerman JE; Raffin TA; Brown JM; Newman RA; Etiz BB; Sikic BI
Cancer Res; 1986 Apr; 46(4 Pt 1):1748-53. PubMed ID: 2418953
[TBL] [Abstract][Full Text] [Related]
5. Lidocaine potentiation of bleomycin A2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells.
Lazo JS; Braun ID; Meandzija B; Kennedy KA; Pham ET; Smaldone LF
Cancer Res; 1985 May; 45(5):2103-9. PubMed ID: 2580616
[TBL] [Abstract][Full Text] [Related]
6. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
Tanaka N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
8. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin.
Sebti SM; Jani JP; Mistry JS; Gorelik E; Lazo JS
Cancer Res; 1991 Jan; 51(1):227-32. PubMed ID: 1703034
[TBL] [Abstract][Full Text] [Related]
9. Substrate specificity of bleomycin hydrolase.
Sebti SM; DeLeon JC; Ma LT; Hecht SM; Lazo JS
Biochem Pharmacol; 1989 Jan; 38(1):141-7. PubMed ID: 2462878
[TBL] [Abstract][Full Text] [Related]
10. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
Robson CN; Hoban PR; Harris AL; Hickson ID
Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220
[TBL] [Abstract][Full Text] [Related]
11. Bleomycin hydrolase activity and cytotoxicity in human tumors.
Lazo JS; Boland CJ; Schwartz PE
Cancer Res; 1982 Oct; 42(10):4026-31. PubMed ID: 6179595
[TBL] [Abstract][Full Text] [Related]
12. Bleomycin hydrolase activity in pulmonary cells.
Lazo JS; Merrill WW; Pham ET; Lynch TJ; McCallister JD; Ingbar DH
J Pharmacol Exp Ther; 1984 Dec; 231(3):583-8. PubMed ID: 6209387
[TBL] [Abstract][Full Text] [Related]
13. [Mechanism of action and resistance of antineoplastic agents].
Tanaka N
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2245-51. PubMed ID: 6195971
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
15. Damage and repair induced by bleomycin in the domain of human amplified MYC oncogenes.
Bianchi NO; Bianchi MS; López-Larraza D; Alitalo K; de la Chapelle A
Cancer Res; 1990 Apr; 50(8):2379-84. PubMed ID: 1690597
[TBL] [Abstract][Full Text] [Related]
16. [Sensitivity to bleomycin of human cultured tumor cells and analysis of related factors].
Urade M; Sugi M; Shirasuna K; Sugiyama M; Miyazaki T
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2382-8. PubMed ID: 6195972
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of bleomycin hydrolase by an epitope-specific antibody.
Morris G; Mistry JS; Jani JP; Mignano JE; Sebti SM; Lazo JS
Mol Pharmacol; 1992 Jul; 42(1):57-62. PubMed ID: 1378925
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells.
Tueni EA; Newman RA; Baker FL; Ajani JA; Fan D; Spitzer G
Cancer Res; 1989 Mar; 49(5):1099-102. PubMed ID: 2465080
[TBL] [Abstract][Full Text] [Related]
19. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
Gutierrez PL; Wilder PJ; Biswal N
Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
[TBL] [Abstract][Full Text] [Related]
20. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells.
Pei Z; Calmels TP; Creutz CE; Sebti SM
Mol Pharmacol; 1995 Oct; 48(4):676-81. PubMed ID: 7476893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
